Reduced Genome E. coli for Soluble CRM197 Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing CRM197, a crucial protein for vaccines and potential cancer therapy, face challenges in achieving high yields, particularly in E. coli, leading to high production costs and supply shortages, which hinder vaccination programs and therapeutic development.
Innovation Solution
A method involving a reduced genome E. coli host with specific modifications, including deletion of certain DNA segments and correction of frameshift mutations, is used to express CRM197, directing the protein to the periplasm where it can be efficiently produced in soluble form, achieving yields of up to 10 grams per liter.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CRM197 is produced in E. coli using conventional methods, then production cost is reduced, but yield is low and supply is insufficient
Solution Approach 1:
The patent modifies multiple parameters of the E. coli host system including genome reduction (deleting specific DNA segments), correcting frameshift mutations in the ilvG gene, and optimizing the expression system. These parameter changes collectively enable high-yield production of soluble CRM197, achieving yields of at least 1 gram per liter while maintaining cost-effective manufacturing processes
2Productivity
If CRM197 is produced in C. diphtheriae, then yield is moderate, but biosafety requirements increase and cost increases
Solution Approach 1:
The patent replaces the C. diphtheriae production system with E. coli, a safer and more controllable host organism. By using a reduced genome E. coli strain with targeted deletions and corrected mutations, the system achieves comparable or superior yields without the biosafety concerns associated with C. diphtheriae, effectively substituting a hazardous production system with a safe one
3Productivity
If CRM197 is produced as insoluble form in E. coli, then yield is moderate, but conversion to soluble form is inefficient
Solution Approach 1:
The patent implements preliminary actions by modifying the E. coli host genome before CRM197 expression, including deleting specific DNA segments and correcting the ilvG frameshift mutation. These pre-modifications create an optimized cellular environment that directly promotes efficient production of soluble CRM197, eliminating the need for subsequent conversion steps from insoluble to soluble form
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3C
AI summary
Rediced genome or native K12 strain E. coli bacteria comprising expression vectors encoding a recombinant CRM197 protein and their use in the production of CRM 197 is provided. The CRM 197 protein may be fused to a signal sequence that directs the expressed CRM197 protein to the periplasm of the E. coli host.